Patients harboring an EGFR mutation positive tumor are best treated with an EGFR tyrosine kinase inhibitor (EGFR TKI), as tumor responses are higher and more durable with EGFR TKI than with chemotherapy or immunotherapy [8,9,10,11,12]. Here, EGFR is linked to neoplasm.